Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from IMNM

3 Small-Cap Stocks With Big Growth Potential

Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.

MarketBeat · Dec 13, 2024

3 High-Quality Stocks You'll Kick Yourself Later for Not Buying

Despite recent signs of moderation in inflation, the better-than-expected January jobs data could force the Fed to raise interest rates even further. This is expected to keep the stock market highly volatile in the near term. Given a volatile market backdrop, investing in high-quality stocks AbbVie (ABBV), Cintas (CTAS), and…

StockNews.com · Feb 8, 2023

Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants

Immunome Inc (NASDAQ:IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing. IMM-BCP-01 is currently in Phase 1b testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5, and BA.2. Related: Immunome Shares Rise After Publishing Positive COVID-19 Antibody…

Benzinga · Jul 6, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Short Volatility Alert: Immunome, Inc.

On Modnay, shares of Immunome, Inc. (NASDAQ: IMNM) experienced volatile short activity. After the activity, the stock price went up +0.30% to $3.31. The overall sentiment for IMNM has been Bearish.

Benzinga · May 24, 2022

Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data

Immunome Inc (NASDAQ:IMNM) shares are trading higher after it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the omicron variant (BA.1) when tested in vivo in hamsters. Additional in vitro testing of a SARS-CoV-2 pseudovirus showed that IMM20253, one of the antibodies in Immunome's cocktail, successfully neutralized the omicron subvariant…

Benzinga · May 19, 2022

FDA Lifts Clinical Hold on Immunome's COVID-19 Candidate IND

The FDA has lifted the clinical hold on Immunome Inc's (NASDAQ:IMNM) Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19. Immunome previously announced that the FDA had placed its IND application on clinical hold due to a request for further information related to the preparation and administration of IMM-BCP-01 at clinical sites. …

Benzinga · Mar 11, 2022

Coverage From

People

Jerome Powell

3,483 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Boyd Gaming Corporation

17 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.